Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The gene expression signature of chronic marijuana use

ABSTRACT: The gene expression signature of chronic marijuana use

PROVIDER: PRJNA648978 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12332716.fastq.gz	Fastqsanger.gz
	SRR12332717.fastq.gz	Fastqsanger.gz
	SRR12332718.fastq.gz	Fastqsanger.gz
	SRR12332719.fastq.gz	Fastqsanger.gz
	SRR12332720.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 82

Similar Datasets

The gene expression signature of chronic marijuana use

Project description:Alveolar macrophage (AM) gene expression studies in cigarette smokers have identified dysregulated molecular pathways relevant to clinical outcomes. However, parallel studies in cannabis smokers are limited, despite marijuana’s increasing public health relevance. We performed the first genome-wide gene expression analysis from the lungs of marijuana smokers to test the hypothesis that marijuana is associated with changes in AM gene expression that may contribute to altered immune function. AMs from bronchoalveolar lavage from 15 marijuana smokers, 16 cigarette smokers, and 10 non-smokers were isolated for RNA sequencing. We performed differential expression analysis to identify genes that differed on average between smoking groups, with emphasis on genes associated with M1/M2 macrophage polarization and immunity.

2021-10-02 | GSE155213 | GEO

Differential expression gene signature

Project description:Differential expression gene signature

| PRJNA971197 | ENA

The blood transcriptional signature of chronic HCV

Project description:This SuperSeries is composed of the following subset Series: GSE40184: The blood transcriptional signature of chronic HCV [Affymetrix data] GSE40223: The blood transcriptional signature of chronic HCV [Illumina data] Refer to individual Series

2012-10-22 | E-GEOD-40224 | biostudies-arrayexpress

Expression Signature of Human Endogenous Retroviruses in Chronic Lymphocytic Leukemia

Project description:Expression Signature of Human Endogenous Retroviruses in Chronic Lymphocytic Leukemia

| PRJNA975147 | ENA

Project description:Associations of Chronic Marijuana Use with Changes of Salivary Microbiome

| PRJNA995421 | ENA

Glioma MYC gene signature

Project description:Glioma MYC gene signature

| PRJNA852544 | ENA

Stromal gene signature

Project description:Stromal gene signature predictive for PCa metastasis

| PRJEB19256 | ENA

Gene expression signature that predicts early molecular response failure in chronic phase CML patients on frontline imatinib

Project description:In chronic phase chronic myeloid leukemia (CP-CML) patients treated with frontline imatinib, failure to achieve early molecular response (EMR failure: BCR-ABL1 >10% (IS) at 3 months) is predictive of inferior outcomes. Identifying patients at high-risk of EMR failure at diagnosis provides an opportunity to intensify frontline therapy and potentially avoid EMR failure. We studied blood samples from 96 CP-CML patients at diagnosis and identified 365 genes that were aberrantly expressed in 13 patients who subsequently failed to achieve EMR, with a gene signature significantly enriched for stem cell phenotype (e.g. Myc, b-catenin, Hoxa9/Meis1), cell cycle, and reduced immune response pathways. We selected a 17-gene panel to predict EMR failure and validated this signature on an independent patient cohort. Patients classified as high-risk with our gene expression signature (HR-GES) exhibited significantly higher rates of EMR failure compared to low-risk (LR-GES) patients (78% vs 5%; p<0.0001) with an overall accuracy of 93%. Furthermore, HR-GES patients who received frontline nilotinib had a relatively low rate of EMR failure (10%). However HR-GES patients still had inferior deep molecular response achievement rate by 24 months compared to LR-GES patients. This novel multi-gene signature may be useful for selecting patients at high risk of EMR failure on standard therapy, who may benefit from trials of more potent kinase inhibitors or other experimental approaches.

2019-05-29 | GSE130404 | GEO

Grape Berry Ripening Signature Gene Expression Analysis

Project description:Grape Berry Ripening Signature Gene Expression Analysis

| PRJNA533801 | ENA

Gene expression signature of colorectal cancer patients

Project description:Gene expression signature of colorectal cancer patients

| PRJNA434408 | ENA